Cantor starts Zosano Pharma with Overweight rating, $12 price target. Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Zosano Pharma with an Overweight rating and $12 price target. The company’s proprietary delivery platform facilitates rapid transcutaneous absorption of drug candidates and is applicable to multiple therapeutic areas, including migraine and other acute symptom settings, and is appropriate for several classes of drugs, Duncan tells investors in a research note. Zosano is on track to file its first new drug application by the end of 2019 with Qtrypta, a drug that has demonstrated “impressive” Phase 3 clinical data, adds the analyst.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.